ArticleBrazilian journal of otorhinolaryngology
HPV genotyping in head and neck cancer: Insights from a Colombian cohort.
Article in Brazilian journal of otorhinolaryngology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the frequency and distribution of Human Papillomavirus (HPV) infection in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) treated at a tertiary hospital in Colombia.
methodsA descriptive cross-sectional study was conducted in 81 patients diagnosed with HNSCC between 2015 and 2021 at Fundación Santa Fe de Bogota, Colombia, as part of the Colombian cohort of the InterCHANGE and HEADSpace study. Formalin-Fixed Paraffin-Embedded (FFPE) tumor samples were analyzed for HPV DNA detection and genotyping. Fifty-nine samples were processed using the HPV-Direct Flow CHIP assay (Master Diagnóstica, Seville, Spain), and 22 with the INNO-LiPA HPV Genotyping Extra assay (Fujirebio, Gothenburg, Sweden). Both techniques identify high- and low-risk HPV genotypes through PCR amplification and reverse hybridization. Immunohistochemistry for p16 was performed in all cases using the anti-p16INK4a (E6H4 clone) antibody, considering strong nuclear and cytoplasmic staining in ≥ 70% of tumor cells as positive. Descriptive statistics included absolute and relative frequencies.
resultsThe mean age was 66-years (±11), and 64.2% were male. The oropharynx was the most frequent tumor location (50.6%, n = 41), followed by the oral cavity (35.8%, n = 29) and larynx (13.6%, n = 11). Overall, 51.9% (n = 42) of tumors were HPV DNA-positive. HPV infection was more frequent in oropharyngeal carcinomas (92.7%, n = 38) than in the oral cavity (6.9%, n = 2) or larynx (18.2%, n = 2). HPV-16 was the predominant genotype (79.4%), followed by HPV-35, HPV-18, and HPV-33. p16 overexpression was observed in 49.4% (n = 40) of cases, mainly in oropharyngeal carcinomas (87.8%, n = 36). Among HPV DNA-positive tumors, 92.5% (n = 37) were also p16-positive.
conclusionsThis study demonstrates a high prevalence of HPV, predominantly HPV-16, in oropharyngeal carcinomas compared with other head and neck sites in our cohort. These results provide baseline data for Colombia and highlight the need for multicenter studies including more heterogeneous populations to guide future prevention and control strategies. LEVEL OF EVIDENCE: 4 (According to the Oxford Centre for Evidence-Based Medicine, 2011).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.